Melphalan 140 mg/m(2) or 200 mg/m(2) for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party

Authors :: Auner, Holger W.
Iacobelli, S.
Sbianchi, Giulia
Knol-Bout, Cora
Blaise, D.
Russell, Nigel H.
Schaap, N.P.M.
Garderet, L.
Kroeger, Nicolaus
Source :: Haematologica, 103, 3, pp. 514-521, Haematologica, 103, 514-521
Publication Year :: 2018
Abstract: Contains fulltext : 190028.pdf (Publisher’s version ) (Open Access)

Subjects :: All institutes and research themes of the Radboud University Medical Center
Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]
GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries)

Tools